Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. ACN

Go back to Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure
(NASDAQ: PGEN) Delayed: 7.70 -0.08 (1.03%)
Previous Close $7.78    52 Week High $ 
Open $7.84    52 Week Low $ 
Day High $7.91    P/E N/A 
Day Low $7.63    EPS $ 
Volume 2,185,276